Evidence map›Paper›PMID 34412166›Full record

Trial reportDrug testing and analysis2022

Orally administered cannabidiol does not produce false-positive tests for Δ

Danielle McCartney, Richard C Kevin, Anastasia S Suraev, Christopher Irwin, Ronald R Grunstein, Camilla M Hoyos, Iain S McGregor

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug testing and analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Detection of ΔDrug testing and analysis · 2024
    Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Danielle McCartneyLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-7783-5220
Richard C KevinLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-4912-4499
Anastasia S SuraevLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.
Christopher IrwinMenzies Health Institute Queensland, School of Health Sciences and Social Work, Griffith University, Gold Coast, Queensland, Australia.
Ronald R GrunsteinCentre for Sleep and Chronobiology, Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Camilla M HoyosBrain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
Iain S McGregorLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many jurisdictions use point-of-collection (POC) oral fluid testing devices to identify driving under the influence of cannabis, indexed by the presence of Δ

Indexed as

Administration, OralAdultCannabidiolChromatography, High Pressure LiquidCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodDronabinolFalse Positive ReactionsFemaleHumansMaleSubstance Abuse DetectionTandem Mass SpectrometryYoung AdultCannabidiolDronabinolcannabidiolcannabisdrug drivingoral fluidpoint-of-collection testing

Identifiers

PMID34412166
PMCPMC9292716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.